Many molecular biomarkers with expression level changes have been identified in breast cancer tissue samples or blood, for example, HER2[ 2], PNCA[ 3], Lipofilin B[ 4], Cyclin D1[ 5], CEACAM6[ 6], Osteopontin-c[ 7], RCP[ 8], and FOXA1[ 9].
Owing to the relatively low rate of recurrence of DCIS, either as in situ or invasive disease, there are a few studies that relate molecular phenotype or biomarker expression of DCIS to the outcome.
During the annotation process, patient tumors and subsequent PDXs are compared at multiple levels, including histomorphology, clinically applicable molecular biomarkers, global gene expression patterns, gene copy number variations, and DNA/chromosomal alterations.
An association between these molecular biomarkers and SSTR2 expression in HGGs, however, has not been studied before.
There are potential implications of previously discovered gastric cancer molecular biomarkers and their expression modulations by respective miRNAs.
This makes TcBBM expression a useful molecular biomarker for determining embryogenic tissue in cacao at a very early stage during SE.
In addition, it will be of interest to evaluate both the prognostic and predictive utilities of PTHLH expression, as a molecular biomarker, for advanced and metastatic clear cell RCC treated with current molecular targeting agents.
Some studies measured molecular biomarker levels directly, some measured the gene expression of molecular biomarkers using mRNA and some used both of these techniques.
We demonstrated significant differences in biomarker expression relative to age and molecular subtypes.
